26 studies found for:    Study of MK-3475
Show Display Options
Rank Status Study
1 Recruiting Study of MK-3475 (Pembrolizumab) in Participants With Advanced Melanoma (MK-3475-041)
Condition: Melanoma
Intervention: Biological: pembrolizumab
2 Recruiting Phase 2 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors
Conditions: MSI Positive Colorectal Cancer;   MSI Negative Colorectal Cancer;   MSI Positive Non-Colorectal Cancers
Intervention: Drug: MK-3475
3 Not yet recruiting Study of MK-3475 (Pembrolizumab) Versus Platinum-based Chemotherapy for Participants With PD-L1-positive Advanced or Metastatic Non-small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)
Condition: Non-small Cell Lung Cancer
Interventions: Biological: pembrolizumab;   Drug: carboplatin;   Drug: paclitaxel;   Drug: pemetrexed
4 Recruiting Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28)
Condition: Solid Tumor
Intervention: Biological: Pembrolizumab
5 Active, not recruiting Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Participants With Advanced Melanoma (P08719/KEYNOTE-002)
Condition: Malignant Melanoma
Interventions: Drug: Pembrolizumab;   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Dacarbazine;   Drug: Temozolomide
6 Recruiting Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-012/KEYNOTE-012)
Conditions: Cancer;   Solid Tumor
Intervention: Drug: Pembrolizumab
7 Recruiting MK-3475 in Melanoma and NSCLC Patients With Brain Metastases
Conditions: Melanoma;   Non-Small Cell Lung Cancer;   Brain Metastases
Intervention: Drug: MK-3475
8 Recruiting A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer (MK-3475-021/KEYNOTE-021)
Condition: Non-small Cell Lung Carcinoma
Interventions: Drug: Pembrolizumab;   Drug: Paclitaxel;   Drug: Carboplatin;   Biological: Bevacizumab;   Drug: Pemetrexed;   Biological: Ipilimumab;   Drug: Erlotinib;   Drug: Gefitinib
9 Recruiting Study of Pembrolizumab (MK-3475) in Participants With Advanced Non-small Cell Lung Cancer (MK-3475-025/KEYNOTE-025)
Condition: Non-small Cell Lung Cancer
Intervention: Biological: Pembrolizumab
10 Recruiting Study of Pembrolizumab (MK-3475) Monotherapy in Participants With Advanced Solid Tumors and Pembrolizumab Combination Therapy in Participants With Advanced Non-small Cell Lung Cancer (MK-3475-011/KEYNOTE-011)
Conditions: Solid Tumor;   Non-small Cell Lung Cancer
Interventions: Drug: Pembrolizumab;   Drug: Cisplatin;   Drug: Pemetrexed;   Drug: Carboplatin;   Drug: Paclitaxel
11 Not yet recruiting A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/KEYNOTE-0036)
Condition: Advanced Solid Tumors
Interventions: Drug: PF-05082566;   Drug: MK-3475
12 Recruiting Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC)
Condition: Carcinoma, Renal Cell
Interventions: Drug: Pazopanib;   Drug: MK-3475
13 Recruiting A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Solid Tumors and Advanced NSCLC (INCB 24360-202 / MK-3475-037 / KEYNOTE-037)
Condition: Cancer, Solid Tumor
Interventions: Drug: MK-3475 and INCB024360;   Drug: MK-3475;   Drug: Placebo
14 Active, not recruiting Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001)
Condition: Cancer, Solid Tumor
Interventions: Drug: Pembrolizumab 1 mg/kg;   Drug: Pembrolizumab 3 mg/kg;   Drug: Pembrolizumab 10 mg/kg;   Drug: Pembrolizumab MEL;   Drug: Pembrolizumab NSCLC;   Drug: Pembrolizumab MEL Low Dose;   Drug: Pembrolizumab MEL High Dose;   Drug: Pembrolizumab NSCLC Low Dose;   Drug: Pembrolizumab NSCLC High Dose;   Drug: Pembrolizumab NSCLC Medium Dose
15 Active, not recruiting Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006)
Condition: Melanoma
Interventions: Drug: Pembrolizumab;   Drug: Ipilimumab
16 Recruiting A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022)
Condition: Melanoma
Interventions: Biological: Pembrolizumab;   Drug: dabrafenib;   Drug: trametinib
17 Not yet recruiting A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer
Condition: Renal Cell Carcinoma
Interventions: Drug: Axitinib;   Drug: MK-3475
18 Recruiting A Study of Pembrolizumab (MK-3475) in Combination With Lenalidomide and Dexamethasone in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023)
Condition: Multiple Myeloma
Interventions: Biological: Pembrolizumab;   Drug: Lenalidomide;   Drug: Dexamethasone
19 Recruiting Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29)
Conditions: Renal Cell Carcinoma;   Melanoma
Interventions: Biological: Pembrolizumab;   Biological: PegIFN-2b;   Biological: Ipilimumab
20 Not yet recruiting Treatment of Advanced Melanoma With MK-3475 and Peginterferon
Condition: Melanoma
Interventions: Drug: MK-3475;   Drug: Peginterferon alfa-2b

Previous Page Studies Shown (1-20) Next Page (21-26) Show next page of results
Indicates status has not been verified in more than two years